Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Audere is closing gaps in HIV care and education with the help of Amy, their artificial intelligence companion designed to ...

Humana has released details about additional, upcoming organizational improvements to encourage a faster prior authorization ...

The Vision Center at Children’s Hospital Los Angeles is developing a protocol for a phase 1 clinical trial for the first gene ...

Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators ...

An expert discusses how choosing between triplet and quadruplet regimens for transplant-ineligible multiple myeloma depends on patient fitness, disease risk, and treatment tolerability. He highlights ...

This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

A national preexposure prophylaxis (PrEP) program would streamline access and improve HIV outcomes but unfortunately never came to pass because of a lack of funding, according to Jeremiah Johnson, ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...

Elevidys is a gene therapy approved to treat Duchenne muscular dystrophy. Last month, Sarapta halted sales of the therapy for non-ambulatory patients.